Pallas Capital Advisors LLC Sells 43,485 Shares of DENTSPLY SIRONA Inc. $XRAY

Pallas Capital Advisors LLC trimmed its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 52.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,036 shares of the medical instruments supplier’s stock after selling 43,485 shares during the period. Pallas Capital Advisors LLC’s holdings in DENTSPLY SIRONA were worth $446,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of XRAY. SG Americas Securities LLC purchased a new position in shares of DENTSPLY SIRONA during the fourth quarter valued at about $1,064,000. Allworth Financial LP grew its holdings in DENTSPLY SIRONA by 66.6% during the 3rd quarter. Allworth Financial LP now owns 10,323 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 4,127 shares in the last quarter. Caerus Investment Advisors LLC bought a new stake in DENTSPLY SIRONA in the 3rd quarter worth approximately $153,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director James D. Forbes acquired 5,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was bought at an average cost of $12.48 per share, with a total value of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gregory T. Lucier bought 27,555 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were acquired at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the completion of the acquisition, the director owned 27,555 shares in the company, valued at $392,383.20. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 70,000 shares of company stock worth $956,437 in the last three months. Corporate insiders own 0.52% of the company’s stock.

Analysts Set New Price Targets

XRAY has been the topic of several research reports. Wells Fargo & Company boosted their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price objective for the company from $13.00 to $17.00 in a research report on Thursday, February 19th. Barclays started coverage on shares of DENTSPLY SIRONA in a research note on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective for the company. Mizuho boosted their target price on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Finally, UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Stock Performance

DENTSPLY SIRONA stock opened at $11.60 on Wednesday. The company has a 50 day moving average price of $12.54 and a 200-day moving average price of $12.17. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $17.18. The company has a market capitalization of $2.32 billion, a PE ratio of -3.87, a P/E/G ratio of 1.32 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.